Hot flashing. Menopausal and female climacteric states
Conditions
Interventions
Intervention 1: Capsule Saffron 30mg/day as intervention group for 6 weeks. Intervention 2: Capsule placebo as intervention group for 6 weeks.
Treatment - Drugs
Placebo
Capsule Saffron 30mg/day as intervention group for 6 weeks
Capsule placebo as intervention group for 6 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: women aged between 45-65 years old; menopause. Exclusion criteria: moderate to severe post-menopausal hot flushing-five episodes per day from 2 months ago; sopping of the mens from 12 month ago; receiving estrogen or progesterone during the last two months; receiving antidepressants during the last month; receving Selective Estrogen Receptor Modulators including raloxifen and tamoxifen during the last month; receiving aromatase inhibitors such as Anastrozole, Letrozole, Exemestane during the last month;receving Leuprolide acetate during the last month; receiving clonidine during the last month; receving gabapentine and pregabalin during the last month; receiving hot flushing reducing medications during the last month; receiving amino acid supplements during the last month.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of hot flashing. Timepoint: Baseline and 2, 4, 6 weeks after beginnig of treatment. Method of measurement: By Hot flash Related Daily Interference. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of depression. Timepoint: Baseline and 2, 4, 6 weeks after beginnig of treatment. Method of measurement: By Hamilton Depression Rating scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProf. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed